Short-term escitalopram treatment and hippocampal volume by Beata R. Godlewska et al.
LETTER TO THE EDITOR
Short-term escitalopram treatment and hippocampal volume
Beata R. Godlewska & Helge W. W. Hasselmann & Artemis Igoumenou &
Ray Norbury & Philip J. Cowen
Received: 19 June 2014 /Accepted: 4 October 2014 /Published online: 18 October 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Major depression has been associated with volume loss in
hippocampal regions in most but not all meta-analyses
(Arnone et al. 2012: Bora et al. 2012). In animal studies,
repeated antidepressant treatment increases hippocampal
neurogenesis (Malberg et al. 2000) but there have been few
longitudinal studies in depressed patients assessing the effects
of antidepressant medication on hippocampal volume.
Recently, however, Arnone and colleagues (2013) re-
ported that 8-week treatment with the selective serotonin
re-uptake inhibitor (SSRI) citalopram in 32 depressed
patients produced a bilateral increase in hippocampal
volume. The aim of the present study was to see if a similar
effect could be demonstrated during short-term treatment with
the SSRI, escitalopram.
We studied 33 unmedicated participants (mean age
29.9, range 20–61 years, 19 female) who were diag-
nosed using the Structured Interview for DSM-IV as
having major depression. Participants were scanned be-
fore and during (mean duration 46 days, range 38–
66 days) treatment with escitalopram, 20 mg daily.
Twenty of the patients were antidepressant naïve. In
the remainder, the mean drug-free interval was
117 weeks (range 8–468 weeks). Clinical assessment
included Beck Depression Inventory (BDI) and
Hamilton Depression Rating Scale (HAM-D). Clinical
response was classified as ≥50 % symptom reduction
from baseline on HAM-D. All participants gave in-
formed consent to the study which was approved by the local
ethics committee.
Participants were scanned at the University of Oxford
Centre for Clinical Magnetic Resonance Research on a 3
Tesla Siemens Trio Scanner with a 12-channel head coil
(Siemens, Germany) and 1-mm3 voxel dimension
(MPRAGE: repetition time = 2040 ms, echo time = 4.68 ms,
flip angle = 8°, field of view = 256 mm). All FMRIB Software
Library (FSL) analyses followed default settings described at
http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSL. FSL-VBM smooth-
ing was performed with an isotropic Gaussian kernel of
2 mm. Hippocampi were automatically segmented using
FSL-FIRST (Patenaude et al. 2011). A general linear model
with 5000 permutations and threshold-free cluster enhance-
ment was performed to assess voxel- and vertex-wise differ-
ences. FSL-FAST was used to estimate intracranial volume
(ICV) by summing grey matter, white matter and cerebrospi-
nal fluid volume and to normalise hippocampal volumes
(hippocampal grey matter mm3/ICV cm3). As VBM may be
less sensitive to subcortical structures, we additionally con-
ducted vertex analysis, using the FIRST tool in FSL, which is
specially designed to analyse shape and volume differences in
subcortical regions (Patenaude et al. 2011). Statistical analyses
were performed using SPSS 21 software (IBM, USA) with t
tests and a two-tailed α=.05.
Of the 33 participants, 20 (61 %) responded during
escitalopram treatment (with 16 remitters following HAM-D
≤7 criterion of remission). Overall, participants showed no
change in hippocampal volume measures after escitalopram.
Examining the treatment responders separately showed a
trend towards reduced normalised hippocampal volume that
was not explained by differences in ICV (Table 1). There was
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no significant correlation between change in normalised hip-
pocampal volume and duration of escitalopram treatment (all
p values >.05). However, the small number of subjects and
restricted duration of treatment means that this lack of corre-
lation should be treated with caution.
In conclusion, we report no change in hippocampal volume
after short-term escitalopram treatment. While the demo-
graphic and clinical characteristics of our patient sample are
comparable to those reported by Arnone et al.(2013), the
discrepancy between our findings could be explained by the
average shorter duration of antidepressant treatment and fixed
escitalopram dose we employed in our study. Previous expo-
sure to antidepressant drug treatment might of course be
important; however, 20 of our patients were antidepressant-
naïve and examining these participants separately also showed
no tendency to an increase in hippocampal volume. In addi-
tion, we do not have a measure of treatment concordance and
it is possible that some of our patients did not take their
medication. Also, it cannot be excluded that methodology
contributed to differences between our results and Arnone
and colleagues; though we conducted a number of different
analyses, none of which showed a trend to an increase in
hippocampal volume after escitalopram treatment.
Escitalopram and citalopram are closely related SSRIs,
with escitalopram being the active isomer of citalopram.
Some meta-analyses have reported superior efficacy of
escitalopram relative to citalopram (Cipriani et al. 2009).
However, there is no reason to think that their effects on brain
morphology would be different.
As noted above, there are relatively few longitudinal stud-
ies of the effects of antidepressant treatment on hippocampal
volume and more are needed. However, while our findings are
negative, they are in broad agreement with an earlier longitu-
dinal investigation that reported no volumetric change in
hippocampus after 7 months of successful SSRI treatment in
22 depressed patients (Vythilingam et al. 2004).
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Table 1 Mean (±standard
deviation) depression scores,
intracranial volume (ICV, cm3)
and hippocampal volume (mm3)
before and during escitalopram
treatment
Pre-treatment On treatmenta t p
Entire sample (n=33)
BDI 31.7±7.2 15.2±11.4 7.007 <.001
HAM-D 23.0±4.6 9.5±7.8 9.118 <.001
ICV 1478.6±158.6 1482.5±129.7 −0.200 .842
Left hippocampus
Absolute 3887.06±553.09 3897.09±545.42 −0.151 .881
Normalised 2.64±0.36 2.64±0.37 0.071 .944
Right hippocampus
Absolute 3874.94±485.70 3869.55±462.71 0.130 .897
Normalised 2.63±0.27 2.62±0.30 0.234 .816
Responders (n=20)
BDI 31.4±6.4 9.3±7.5 10.157 <.001
HAM-D 23.1±5.1 4.4±3.9 13.679 <.001
ICV 1450.6±125.0 1483.2±128.1 −1.509 .148
Left hippocampus
Absolute 3910.13±661.48 3819.95±604.22 0.811 .374
Normalised 2.70±0.41 2.59±0.41 1.638 .102
Right hippocampus
Absolute 3837.22±526.87 3784.96±538.83 0.742 .313
Normalised 2.65±0.32 2.56±0.37 1.802 .057
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aMean treatment duration
46 days, range 38–66 days
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